695 related articles for article (PubMed ID: 28418267)
21. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
Ahn IE; Underbayev C; Albitar A; Herman SE; Tian X; Maric I; Arthur DC; Wake L; Pittaluga S; Yuan CM; Stetler-Stevenson M; Soto S; Valdez J; Nierman P; Lotter J; Xi L; Raffeld M; Farooqui M; Albitar M; Wiestner A
Blood; 2017 Mar; 129(11):1469-1479. PubMed ID: 28049639
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib treatment of CLL: the cancer fights back.
Young RM; Staudt LM
Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
[TBL] [Abstract][Full Text] [Related]
23. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
24. Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
Lenz G
J Clin Oncol; 2017 May; 35(13):1451-1452. PubMed ID: 28291389
[No Abstract] [Full Text] [Related]
25. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Lucas F; Larkin K; Gregory CT; Orwick S; Doong TJ; Lozanski A; Lozanski G; Misra S; Ngankeu A; Ozer HG; Sampath D; Thangavadivel S; Yilmaz SA; Rogers KA; Byrd JC; Woyach JA; Blachly JS
Blood; 2020 Jun; 135(24):2192-2195. PubMed ID: 32232486
[No Abstract] [Full Text] [Related]
26. Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
Famà R; Bomben R; Rasi S; Dal Bo M; Ciardullo C; Monti S; Rossi F; D'Agaro T; Zucchetto A; Gattei V; Gaidano G; Rossi D
Blood; 2014 Dec; 124(25):3831-3. PubMed ID: 25498455
[No Abstract] [Full Text] [Related]
27. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
Jaglowski SM; Jones JA; Nagar V; Flynn JM; Andritsos LA; Maddocks KJ; Woyach JA; Blum KA; Grever MR; Smucker K; Ruppert AS; Heerema NA; Lozanski G; Stefanos M; Munneke B; West JS; Neuenburg JK; James DF; Hall N; Johnson AJ; Byrd JC
Blood; 2015 Aug; 126(7):842-50. PubMed ID: 26116658
[TBL] [Abstract][Full Text] [Related]
28. Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
Ayed AO; Parikh SA
Leuk Lymphoma; 2018 Oct; 59(10):2287-2296. PubMed ID: 29115892
[TBL] [Abstract][Full Text] [Related]
29. A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.
Raghunathan V; Fan G; Kittai AS; Okada C; Danilov AV; Spurgeon SE
Eur J Haematol; 2021 Feb; 106(2):294-297. PubMed ID: 33089525
[TBL] [Abstract][Full Text] [Related]
30. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
[TBL] [Abstract][Full Text] [Related]
31. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Reiff SD; Muhowski EM; Guinn D; Lehman A; Fabian CA; Cheney C; Mantel R; Smith L; Johnson AJ; Young WB; Johnson AR; Liu L; Byrd JC; Woyach JA
Blood; 2018 Sep; 132(10):1039-1049. PubMed ID: 30018078
[TBL] [Abstract][Full Text] [Related]
32. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S; Sutton LA; Ljungström V; Capasso A; Pandzic T; Weström S; Foroughi-Asl H; Skaftason A; Gellerbring A; Lyander A; Gandini F; Gaidano G; Trentin L; Bonello L; Reda G; Bödör C; Stavroyianni N; Tam CS; Marasca R; Forconi F; Panayiotidis P; Ringshausen I; Jaksic O; Frustaci AM; Iyengar S; Coscia M; Mulligan SP; Ysebaert L; Strugov V; Pavlovsky C; Walewska R; Österborg A; Cortese D; Ranghetti P; Baliakas P; Stamatopoulos K; Scarfò L; Rosenquist R; Ghia P
Blood Adv; 2023 Jun; 7(12):2794-2806. PubMed ID: 36696464
[TBL] [Abstract][Full Text] [Related]
33. Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.
Takács F; Kotmayer L; Czeti Á; Szalóki G; László T; Mikala G; Márk Á; Masszi A; Farkas P; Plander M; Weisinger J; Demeter J; Fekete S; Szerafin L; Deák BM; Szaleczky E; Sulák A; Borbényi Z; Barna G
Pathol Oncol Res; 2022; 28():1610659. PubMed ID: 36213161
[No Abstract] [Full Text] [Related]
34. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M; Krantz F; Mantel R; Smith LL; McClanahan F; Harrington BK; Colomer D; Covey T; Byrd JC; Izumi R; Kaptein A; Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA
Clin Cancer Res; 2017 Jun; 23(11):2831-2841. PubMed ID: 27903679
[No Abstract] [Full Text] [Related]
35. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
[TBL] [Abstract][Full Text] [Related]
36. Targeting BTK through microRNA in chronic lymphocytic leukemia.
Bottoni A; Rizzotto L; Lai TH; Liu C; Smith LL; Mantel R; Reiff S; El-Gamal D; Larkin K; Johnson AJ; Lapalombella R; Lehman A; Plunkett W; Byrd JC; Blachly JS; Woyach JA; Sampath D
Blood; 2016 Dec; 128(26):3101-3112. PubMed ID: 27756747
[TBL] [Abstract][Full Text] [Related]
37. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
38. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
39. B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.
Woyach JA; Ghia P; Byrd JC; Ahn IE; Moreno C; O'Brien SM; Jones D; Cheung LWK; Chong E; Kwei K; Dean JP; James DF; Wiestner A
Clin Cancer Res; 2023 Aug; 29(16):3065-3073. PubMed ID: 37314786
[TBL] [Abstract][Full Text] [Related]
40. Targeted therapies: ibrutinib resonates with us.
Villanueva MT
Nat Rev Clin Oncol; 2014 Jul; 11(7):380. PubMed ID: 24935013
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
